We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Dynavax's Two Phase 3 HEPLISAV Trials Cleared by DSMB to Continue to Study Completion

Product News   Feb 24, 2011

 
Dynavax's Two Phase 3 HEPLISAV Trials Cleared by DSMB to Continue to Study Completion
 
 
FURTHER INFORMATION
 
 
 

Related Product News

GE Healthcare, Vanderbilt University Medical Center Partner for Safer, More Precise Immunotherapy Cancer Treatment

Product News

Artificial Intelligence (AI)-powered applications will help predict how individual patients will respond to immunotherapies in advance of treatment.

READ MORE

GenScript Launches Novel Technology Licensed from Amgen for Accelerating Protein and Antibody Purification

Product News

AmMag SA magnetic purification system first to offer high throughput of large samples, accelerating early stage drug development.

READ MORE

New Digital Marketplace for Life Science Products – Built with Scientists in Mind

Product News

Customer-centric, science-driven platform opens market with scientifically informed purchasing.

READ MORE

Like what you just read? You can find similar content on the communities below.

Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE